Holen Sie sich die Stockscreener-App
34.61
2.73%
-0.97
Handel nachbörslich:
34.61
Schlusskurs vom Vortag:
$35.58
Offen:
$35.27
24-Stunden-Volumen:
529.48K
Relative Volume:
0.77
Marktkapitalisierung:
$1.93B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$23.68M
KGV:
82.40
EPS:
0.42
Netto-Cashflow:
$108.67M
1W Leistung:
-2.40%
1M Leistung:
-12.34%
6M Leistung:
-34.41%
1J Leistung:
-33.86%
1-Tages-Spanne:
$34.24
$35.27
1-Wochen-Bereich:
$34.00
$35.88
52-Wochen-Spanne:
$32.48
$64.47
Livanova Plc Stock (LIVN) Company Profile
Firmenname
Livanova Plc
Sektor
Branche
Telefon
4402033250662
Adresse
20 EASTBOURNE TERRACE, LONDON
Vergleichen Sie LIVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
34.61 | 1.93B | 1.24B | 23.68M | 108.67M | 0.42 |
|
ABT
Abbott Laboratories
|
129.89 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.58 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
339.59 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.80 | 105.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.20 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | Eingeleitet | Goldman | Buy |
| 2024-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | Bestätigt | Needham | Buy |
| 2024-02-20 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-02-24 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-03 | Eingeleitet | Goldman | Buy |
| 2021-08-20 | Bestätigt | Needham | Buy |
| 2021-07-20 | Hochstufung | Needham | Hold → Buy |
| 2021-03-03 | Herabstufung | Berenberg | Buy → Hold |
| 2021-01-05 | Herabstufung | Needham | Buy → Hold |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-26 | Bestätigt | Needham | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-08 | Eingeleitet | Stifel | Buy |
| 2018-05-31 | Bestätigt | Needham | Buy |
| 2018-02-28 | Bestätigt | Needham | Buy |
Alle ansehen
Livanova Plc Aktie (LIVN) Neueste Nachrichten
Mizuho Adjusts Price Target for LivaNova (LIVN) Ahead of Q1 Preview | LIVN Stock News - GuruFocus
What Is LivaNova PLC's (NASDAQ:LIVN) Share Price Doing? - Yahoo Finance
LivaNova PLC (LIVN): Among the Best UK Stocks to Buy According to Billionaires - Insider Monkey
Cardiovascular Devices Market Demand, Growth and Future Scope - openPR.com
Vagus Nerve Stimulators Market Deep Research Report with - openPR.com
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For - simplywall.st
Aortic Stenosis Market to Witness Massive Growth by 2032 | - openPR.com
10 Best UK Stocks to Buy According to Billionaires - Insider Monkey
LivaNova PLC: Excellent Revenue Earner, Some Short-Term Litigation Concerns (LIVN) - Seeking Alpha
LivaNova stock plunges to 52-week low, touches $36.18 By Investing.com - Investing.com Canada
LivaNova stock plunges to 52-week low, touches $36.18 - Investing.com Australia
Vagus Nerve Stimulators Market Size, Growth Trends and Report - openPR.com
(LIVN) Trading Advice - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Bought by Prudential Financial Inc. - MarketBeat
Implantable Cardioverter Defibrillators Market to Witness - openPR.com
LivaNova (NASDAQ:LIVN) Upgraded at StockNews.com - MarketBeat
LivaNova to Announce First-Quarter 2025 Results - Sharewise
LivaNova (NASDAQ:LIVN) investors are sitting on a loss of 50% if they invested three years ago - Yahoo Finance
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now? - simplywall.st
LivaNova PLC (LIVN) Shares Up 0.4% on Mar 19 - GuruFocus.com
Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% by 2030, estimates DelveInsight - The Globe and Mail
Vagus Nerve Stimulators Market is Expected to Witness Positive - openPR
Jefferies cuts Livanova stock price target to $74 from $80 - Investing.com India
Barclays maintains Livanova stock with $56 target, cites clarity By Investing.com - Investing.com South Africa
Jefferies cuts Livanova stock price target to $74 from $80 By Investing.com - Investing.com Australia
LivaNova to record $363 million liability after court ruling By Investing.com - Investing.com Australia
Needham maintains Livanova buy rating, $64 target amid liability By Investing.com - Investing.com Australia
Barclays Maintains Livanova (LIVN) at Equalweight - StreetInsider.com
Barclays Starts Livanova (LIVN) at Equalweight - StreetInsider
Needham maintains Livanova buy rating, $64 target amid liability - Investing.com
LivaNova to record $363 million liability after court ruling - Investing.com
LivaNova Faces €333 Million Liability Ruling - TipRanks
Supreme Court Rules LivaNova Not Liable For 157 Mln Euros Payments In Environmental Liabilities Case - Marketscreener.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles - Investing.com Australia
Cardiovascular Devices Market Booming with Technological - openPR
Autotransfusion Devices and Consumables Market is Estimated - openPR
LivaNova’s SWOT analysis: medical tech firm’s stock faces growth and legal hurdles By Investing.com - Investing.com South Africa
LivaNova PLC (NASDAQ:LIVN) Shares Sold by Bank of New York Mellon Corp - Defense World
Vagus Nerve Stimulators Market Generated Opportunities, - openPR
LivaNova at Barclays Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
LivaNova at Barclays Conference: Strategic Growth and Innovation - Investing.com India
When the Price of (LIVN) Talks, People Listen - Stock Traders Daily
Goldman Sachs maintains Livanova buy rating, $55 target By Investing.com - Investing.com UK
Barclays Cuts LivaNova (NASDAQ:LIVN) Price Target to $56.00 - Defense World
Finanzdaten der Livanova Plc-Aktie (LIVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Livanova Plc-Aktie (LIVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
| KOZY WILLIAM A | Director |
Mar 30 '25 |
Option Exercise |
0.00 |
1,034 |
0 |
28,496 |
| Hutchinson Michael Damon | Chief Legal Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
2,930 |
0 |
6,686 |
| Shvartsburg Alex | Chief Financial Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
11,083 |
0 |
30,196 |
| Poletti Franco | President, Cardiopulmonary |
Mar 30 '25 |
Option Exercise |
0.00 |
1,257 |
0 |
8,475 |
| Hutchinson Michael Damon | Chief Legal Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
2,254 |
0 |
4,540 |
| Poletti Franco | President, Cardiopulmonary |
Dec 15 '24 |
Option Exercise |
0.00 |
967 |
0 |
7,634 |
| Barry James Christopher | Director |
Dec 15 '24 |
Option Exercise |
0.00 |
1,709 |
0 |
1,709 |
| Shvartsburg Alex | Chief Financial Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
613 |
0 |
19,342 |
| Bianchi Francesco | Director |
Dec 11 '24 |
Sale |
50.99 |
1,250 |
63,738 |
7,522 |
1.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):